28 results
Thumbnail

D3.181 - Oral Immunotherapy for food allergy through a personalised approach

Thumbnail

D3.182 - Initiating Sublingual Immunotherapy in Pre-Adolescence (

Thumbnail

D3.193 - Dual Blockade of TSLP and IL11 with a bispecific antibody: A Promising Strategy for the Treatment of Asthma and Other Airway Disorders

Thumbnail

D3.194 - Carry-Over Effect of House Dust Mite (HDM) Immunotherapy for Allergic Respiratory Conditions in Pediatric and Adolescent Populations: A Systematic Review and Narrative Synthesis

Thumbnail

D3.189 - Oral Immunotherapy–Associated Eosinophilic Esophagitis: A Pediatric Case Report

Thumbnail

D3.183 - Determination of IgE antibodies against recombinant allergens (Phl p 1 and Phl p 5) in a random sample of patients from Madrid with pollinosis before and after one year of subcutaneous immunotherapy

Thumbnail

D3.184 - Comparative immunogenicity of mixed versus individual extracts from the storage mites Acarus siro and Tyrophagus putrescentiae

Thumbnail

D3.185 - Clinical Characteristics of Patients with Hymenoptera Venom Allergy Treated with Venom Immunotherapy: A Retrospective Study

Thumbnail

D3.187 - Sustained Clinical Benefit of Allergen Immunotherapy in Allergic Rhinitis: A Real-Life Study

Thumbnail

D3.188 - Real-Life Effectiveness of Subcutaneous Allergen Immunotherapy Assessed by Medication Consumption: A Retrospective Cohort Study

Thumbnail

D3.190 - Protocol for a real-world Study to Track Response to Oralair in Naïve patients with Grass pollen allergy (STRONG) in the Netherlands

Thumbnail

D3.191 - Demonstrating the Stability of Allergoids, the Next Generation of Allergen Therapy

Thumbnail

D3.192 - Safety of AIT with Depigmented-polymerized extracts in patients with severe allergic asthma. A subanalysis of the SAGITAL study

Thumbnail

D3.195 - Building expert consensus on the positioning of allergen immunotherapy (AIT) within a treatment paradigm for allergic rhinitis/rhinoconjunctivitis led by disease remission: A Delphi consensus

Thumbnail

D3.196 - Safety of subcutaneous immunotherapy with purified native protein Cup a 1, a major allergen of Cupressus arizonica: 6-year real-world data

Thumbnail

D3.213 - Sustained effectiveness of the 300 IR house dust mite sublingual tablet over 2 treatment years in a real-world data setting – results of a non-interventional study

Thumbnail

D3.198 - Challenges of using clinical scores as primary endpoints in allergology trials

Thumbnail

D3.199 - Severe systemic allergic reaction following violation of elimination diet in a patient with sensitization despite achieved remission on allergen-specific immunotherapy

Thumbnail

D3.200 - Broad profile of olive pollen sensitisation as a key factor in immunotherapy failure

Thumbnail

D3.201 - Subcutaneous immunotherapy with a depigmented cat allergoid is safe in patients with cat allergy and beneficial for mental health in adolescents